EARNEST Partners’s HCA Healthcare HCA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-146
Closed -$35.9K – 634
2023
Q3
$35.9K Hold
146
– – ﹤0.01% 404
2023
Q2
$44.3K Hold
146
– – ﹤0.01% 361
2023
Q1
$38.5K Hold
146
– – ﹤0.01% 371
2022
Q4
$35K Hold
146
– – ﹤0.01% 379
2022
Q3
$27K Hold
146
– – ﹤0.01% 398
2022
Q2
$25K Hold
146
– – ﹤0.01% 417
2022
Q1
$37K Hold
146
– – ﹤0.01% 373
2021
Q4
$38K Hold
146
– – ﹤0.01% 373
2021
Q3
$35K Hold
146
– – ﹤0.01% 378
2021
Q2
$30K Hold
146
– – ﹤0.01% 405
2021
Q1
$27K Hold
146
– – ﹤0.01% 405
2020
Q4
$24K Hold
146
– – ﹤0.01% 411
2020
Q3
$18K Hold
146
– – ﹤0.01% 428
2020
Q2
$14K Hold
146
– – ﹤0.01% 477
2020
Q1
$13K Hold
146
– – ﹤0.01% 460
2019
Q4
$22K Hold
146
– – ﹤0.01% 431
2019
Q3
$18K Hold
146
– – ﹤0.01% 459
2019
Q2
$20K Hold
146
– – ﹤0.01% 446
2019
Q1
$19K Hold
146
– – ﹤0.01% 449
2018
Q4
$18K Hold
146
– – ﹤0.01% 433
2018
Q3
$20K Hold
146
– – ﹤0.01% 437
2018
Q2
$15K Hold
146
– – ﹤0.01% 479
2018
Q1
$14K Hold
146
– – ﹤0.01% 493
2017
Q4
$13K Buy
+146
New +$11.7K ﹤0.01% 498
2017
Q1
– Sell
-146
Closed -$11K – 520
2016
Q4
$11K Buy
+146
New +$10.9K ﹤0.01% 501

Other funds holding HCA

EARNEST Partners's HCA Position: Q4 2023 in Review

EARNEST Partners sold out of HCA Healthcare (HCA) in Q4 2023, closing a stake of 146 shares — an estimated $35.9K sold.

EARNEST Partners first reported a position in HCA in Q4 2016 and held it in 25 quarters. The position peaked at $44.3K in Q2 2023. 1,057 funds tracked by Wall St. Rank hold HCA as of Q4 2023.

  • EARNEST Partners reported no remaining HCA Healthcare position as of Q4 2023 after selling out during the quarter.
  • EARNEST Partners sold 146 HCA Healthcare shares in Q4 2023, an estimated $35.9K.
  • EARNEST Partners first reported a position in HCA Healthcare in Q4 2016 and held it in 25 quarters.
  • EARNEST Partners's HCA Healthcare position peaked at $44.3K in Q2 2023.
  • 1,057 funds tracked by Wall St. Rank held HCA Healthcare as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.